Loading…
NBTX
Nanobiotix S.A.
NASDAQ· Healthcare· Biotechnology
$41.23-8.70%
Key metrics
- Market cap
- $2.09B
- P/E
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- —
- EPS
- -$0.59
- ROE
- —
- Profit margin
- -73.52%
- Revenue growth
- —
- Beta
- 0.57
- 52-week high
- $57.14
- 52-week low
- $8.03
History
How the company evolved, year by year. Revenue and debt come from the annual statements; dividends from the payments themselves, which reach further back.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
About the company
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.
- 100
- Paris, France
Company description provided by Yahoo Finance.